{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:21:27Z","timestamp":1756462887939,"version":"3.44.0"},"reference-count":15,"publisher":"BMJ","issue":"5","funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL007057-46"],"award-info":[{"award-number":["HL007057-46"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,5,3]]},"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:p>The tyrosine kinase inhibitor dasatinib is approved for the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL). Patients on dasatinib can rarely develop a form of benign reversible reactive lymphadenopathy termed follicular lymphoid hyperplasia (FLH). Here, we describe a patient with Ph+ ALL who developed follicular lymphoma (FL) after prolonged treatment with dasatinib and who had complete remission of FL after discontinuation of dasatinib. This case suggests that dasatinib-associated FLH could be a premalignant condition that can transform into FL. Moreover, withdrawal of dasatinib may be sufficient for remission of dasatinib-associated FL.<\/jats:p>","DOI":"10.1136\/bcr-2022-252739","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T11:00:21Z","timestamp":1684321221000},"page":"e252739","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Dasatinib-associated follicular lymphoma in a patient with B-cell acute lymphoblastic leukaemia"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6442-0475","authenticated-orcid":false,"given":"Katherine Ismei","family":"Zhou","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Duke University Health System, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyu","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapy, Duke University Health System, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jadee Lee","family":"Neff","sequence":"additional","affiliation":[{"name":"Department of Pathology, Duke University Health System, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Galal","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapy, Duke University Health System, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"2025082710444601000_16.5.e252739.1","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"key":"2025082710444601000_16.5.e252739.2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-513879"},{"key":"2025082710444601000_16.5.e252739.3","unstructured":"Knott A , Liu M , Ascensao J , et al . Case report of dasatinib-induced follicular lymphoid hyperplasia. AVAHO Meet, 2014: Abstract 44."},{"key":"2025082710444601000_16.5.e252739.4","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/PAS.0000000000000488","article-title":"Dasatinib-related follicular hyperplasia: an underrecognized entity with characteristic morphology","volume":"39","author":"Ozawa","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"2025082710444601000_16.5.e252739.5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000375150","article-title":"Lymphoproliferative disorders in patients with chronic myeloid leukemia: a single-center case series","volume":"134","author":"Alshehry","year":"2015","journal-title":"Acta Haematol"},{"key":"2025082710444601000_16.5.e252739.6","doi-asserted-by":"crossref","unstructured":"Bouquet E , Jourdain A , Machet M-C , et al . Dasatinib-associated follicular lymphoid hyperplasia: first pediatric case report and literature review. Pediatr Blood Cancer 2017;64. doi:10.1002\/pbc.26597","DOI":"10.1002\/pbc.26597"},{"key":"2025082710444601000_16.5.e252739.7","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s00277-017-3105-8","article-title":"Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia","volume":"96","author":"Iurlo","year":"2017","journal-title":"Ann Hematol"},{"key":"2025082710444601000_16.5.e252739.8","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000022791","article-title":"Dasatinib associated lymphadenopathy in a chronic myeloid leukemia patient: a case report","volume":"99","author":"Pilalas","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2025082710444601000_16.5.e252739.9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016003889"},{"key":"2025082710444601000_16.5.e252739.10","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/leu.2016.20","article-title":"Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML study IV","volume":"30","author":"Miranda","year":"2016","journal-title":"Leukemia"},{"key":"2025082710444601000_16.5.e252739.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-362889"},{"key":"2025082710444601000_16.5.e252739.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-881961"},{"key":"2025082710444601000_16.5.e252739.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2014.10.021"},{"key":"2025082710444601000_16.5.e252739.14","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1002\/cncr.23097","article-title":"Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials","volume":"110","author":"Tavernier","year":"2007","journal-title":"Cancer"},{"key":"2025082710444601000_16.5.e252739.15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830310215"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-252739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T17:44:52Z","timestamp":1756316692000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-252739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,17]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1136\/bcr-2022-252739"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-252739","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}